On Monday, March 26 at the American College of Cardiology’s (ACC's) 61st annual scientific session, Dr. Susheel Kodali, co-director of the Heart Valve Center at Columbia University Medical Center/New York Presbyterian Hospital, presented two-year results of Edwards Lifesciences’ PARTNER trial to a packed auditorium of physicians, administrators, and industry representatives, all eagerly awaiting these findings.
At last year’s ACC conference in New Orleans, one-year results of PARTNER Cohort A indicated transcatheter aortic valve replacement’s (TAVR’s) non-inferiority to traditional aortic valve replacement (AVR) surgery in terms of all-cause mortality and treatment benefit; this cohort consisted of 699 high-risk patients randomized to TAVR (348) or AVR (351).
ACC 2012: TAVR maintains strong performance at two years; ADVANCE trial supports CoreValve
Over the weekend, the American College of Cardiology (ACC) held their annual conference in Chicago, Ill. The widely-attended meeting offered exciting clinical data on drugs and devices from more than 18 clinical trials.
ACC 2012: CPORT-E results show primary PCI to be safe and effective without onsite surgery
The 2012 Congress on Women’s Health was held on March 16-18 in Washington, D.C., bringing together physician and nursing leaders from across the country to discuss various topics in women’s health. As providers are seeing more complicated cases in their patients, sessions on cancer screening, chronic disease, and gynecologic care emphasized a greater focus on “whole person” care.
Report from the 2012 Women's Health Congress: Caring for the 'whole woman'